• Explore /
  • Poster
  • / Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Abstract Poster

Authors

null

David James McConkey

Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD

David James McConkey , Woonyoung Choi , Susan Halabi , Bin Luo , Hikmat A. Al-Ahmadie , Jonathan E. Rosenberg , Jack Mountain , Ashley Marie Regazzi , Megan Fong , Gopa Iyer , Eliezer Mendel Van Allen , Kent William Mouw , Yujia Wen , Linda McCart , Karla V. Ballman , Himisha Beltran , Michael J. Morris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4562)

DOI

10.1200/JCO.2022.40.16_suppl.4562

Abstract #

4562

Poster Bd #

53

Abstract Disclosures

Similar Posters

First Author: Aiwu He

First Author: Satoshi Nara

Poster

2022 ASCO Annual Meeting

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

First Author: Gopa Iyer

First Author: Hiroshi Kitamura